Russell Investments Group Ltd. boosted its position in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 3,599.8% during the second quarter, Holdings Channel reports. The firm owned 283,513 shares of the company’s stock after buying an additional 275,850 shares during the period. Russell Investments Group Ltd.’s holdings in Pacira Pharmaceuticals were worth $13,524,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Pacira Pharmaceuticals by 28,922.7% in the first quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock worth $145,180,000 after buying an additional 3,172,817 shares during the period. Vanguard Group Inc. boosted its stake in shares of Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock worth $130,420,000 after buying an additional 112,853 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Pacira Pharmaceuticals by 0.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,608,847 shares of the company’s stock worth $73,363,000 after buying an additional 5,166 shares during the period. State Street Corp boosted its stake in shares of Pacira Pharmaceuticals by 2.7% in the first quarter. State Street Corp now owns 1,107,356 shares of the company’s stock worth $50,499,000 after buying an additional 28,663 shares during the period. Finally, Macquarie Group Ltd. boosted its stake in shares of Pacira Pharmaceuticals by 6.7% in the first quarter. Macquarie Group Ltd. now owns 1,074,770 shares of the company’s stock worth $49,010,000 after buying an additional 67,321 shares during the period.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded down 0.83% during mid-day trading on Friday, hitting $35.90. The stock had a trading volume of 360,327 shares. The company has a 50-day moving average of $44.96 and a 200-day moving average of $45.30. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.95 and a 12-month high of $58.95. The stock’s market cap is $1.45 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. The firm had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the company earned $0.21 earnings per share. On average, analysts anticipate that Pacira Pharmaceuticals, Inc. will post ($0.13) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/pacira-pharmaceuticals-inc-pcrx-shares-bought-by-russell-investments-group-ltd/1474106.html.

PCRX has been the subject of a number of research analyst reports. Mizuho reissued a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 15th. ValuEngine cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BidaskClub cut Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 21st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $54.50.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 1,877 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $81,311.64. Following the transaction, the chief accounting officer now owns 13,773 shares of the company’s stock, valued at $596,646.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Lauren Bullaro Riker sold 601 shares of the company’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $26,035.32. The disclosure for this sale can be found here. Insiders sold 50,564 shares of company stock valued at $2,506,682 over the last 90 days. 6.60% of the stock is currently owned by insiders.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.